scholarly journals Comparing the effects of low-dose contraceptive pills to control dysfunctional uterine bleeding by oral and vaginal methods

2013 ◽  
Vol 29 (5) ◽  
Author(s):  
Ferdous Mehrabian ◽  
Fariba Abbassi
Keyword(s):  
Low Dose ◽  
Uterine Bleeding ◽  
Dysfunctional Uterine Bleeding ◽  
Contraceptive Pills

scholarly journals Comparative study of ormeloxifene and low dose oral contraceptive pill for the treatment of dysfunctional uterine bleeding in peri-menopausal age group

2021 ◽  
Vol 10 (8) ◽  
pp. 3112
Author(s):  
Maitri Shah ◽  
Chirayu Parmar ◽  
Riddhi Gor
Keyword(s):  
Oral Contraceptive ◽  
Blood Loss ◽  
Uterine Bleeding ◽  
T Test ◽  
Wilcoxon Test ◽  
Age Group ◽  
Dysfunctional Uterine Bleeding ◽  
Oral Contraceptive Pills ◽  
Combined Oral Contraceptive ◽  
Contraceptive Pills

Background: Dysfunctional uterine bleeding (DUB) is the most common menstrual disorder of women in any age group and is a diagnosis of exclusion. Medical management of menorrhagia is a difficult task as there are wide variations in the available drugs and a lot of different regimes are available. Present study evaluates efficacy and safety of ormeloxifene a selective estrogen receptor modulator (SERMs) as compared to combined oral contraceptive pills in treatment of dysfunctional uterine bleeding in perimenopausal women.Methods: Total 60 patients meeting with our inclusion and exclusion criteria were enrolled in the study over a time period of 6 months and were further divided randomly into two groups. One group was given Ormeloxifene and the other group was treated with combined oral contraceptive pills (COCP) over a period of six months. The outcome variables noted were pictorial blood loss assessment chart (PBAC) score, Hb level and combined endometrial thickness (CET). Quantitative variables were compared using independent t test/Mann-Whitney test between the two groups and paired t Test/Wilcoxon test was used for comparison between pre and post within the group.Results: Both ormeloxifene and COCP significantly reduce blood loss in these patients evidenced by decrease of PBAC score, rise in hemoglobin levels and decrease in CET levels. However, ormeloxifene was found to be superior to COCP in reducing the menstrual blood loss. Ormeloxifene was also tolerated better compared to COCP with fewer side effects experienced by patients.

scholarly journals Ormeloxifene versus combined oral contraceptive pills to control blood loss in cases of dysfunctional uterine bleeding

2019 ◽  
Vol 8 (12) ◽  
pp. 4909
Author(s):  
Ankita Gupta ◽  
Rishika Raj
Keyword(s):  
Oral Contraceptive ◽  
Blood Loss ◽  
Endometrial Thickness ◽  
Uterine Bleeding ◽  
Menstrual Blood ◽  
Control Group ◽  
Dysfunctional Uterine Bleeding ◽  
Oral Contraceptive Pills ◽  
Combined Oral Contraceptive ◽  
Contraceptive Pills

Background: Dysfunctional uterine bleeding is one of the most often encountered gynecologic problems causing anemia, reduced quality of life and unnecessary hysterectomies. A prospective study was conducted on women with DUB to study the effect of ormeloxifene versus combined oral contraceptive pills in controlling blood loss in them.Methods: 100 Women with DUB were enrolled randomly in three groups. After baseline assessment each patient in group A was treated with iron tablets, containing 100 mg elemental iron and folic acid 1.5 mg, for three months and were termed as control group. Group B patients were treated with ormeloxifene in dose of 60 mg twice a week for twelve weeks. Group C patients were treated with combined oral contraceptive pills for twenty- one days starting from third day of their LMP. The treatment was continued for three consecutive cycles. The efficacy of the studied drugs was analyzed by comparing the baseline and post treatment PBAC score, haemoglobin level and endometrial thickness, using appropriate statistical tests.Results: Ormeloxifene was more effective than only iron or combined oral contraceptive therapy in controlling menstrual blood loss (79.11% versus 58.57%). There was a reduction in endometrial thickness in group receiving ormeloxifene as well as in the group receiving combined oral contraceptive pills (p=0.486), however this was statistically not significant.Conclusions: Ormeloxifene was significantly better than combined OCP in reduction of menstrual blood flow in cases of DUB. It has better compliance and marked improvement in subjective symptoms as compared to OCP.

scholarly journals A study to compare the efficacy of ormeloxifene with norethisterone and conventional oral contraceptive pills

2017 ◽  
Vol 6 (10) ◽  
pp. 4469
Author(s):  
Monica Chauhan ◽  
Neena Gupta ◽  
Seema Dwivedi ◽  
Shaily Agarwal
Keyword(s):  
Oral Contraceptive ◽  
Comparative Evaluation ◽  
Randomized Study ◽  
Uterine Bleeding ◽  
Subjective Improvement ◽  
Dysfunctional Uterine Bleeding ◽  
Oral Contraceptive Pills ◽  
Group Iii ◽  
Contraceptive Pills ◽  
Group I

Background: Dysfunctional uterine bleeding is one of the commonest conditions for which patients seek advice in gynaecological outpatient department. Objective of present study was comparative evaluation of ormeloxifene with norethisterone and conventional oral contraceptive pills in dysfunctional uterine bleeding.Methods: This randomized study was conducted on 300 cases of dysfunctional uterine bleeding and they were distributed into three groups. group I were given ormeloxifene 60 mg biweekly for first 12 weeks followed by 60 mg weekly for next 12 weeks. Group II were given norethisterone 5 mg BD from 5th to 25th day of cycle and group III were given oral contraceptive pills from 5th to 25th day of cycle.Results: Subjective improvement was outstanding in group I in comparison to other two groups. There was also statistically significant increase in Hb g/dl and statistically significant decrease in endometrial thickness.Conclusions: Ormeloxifene was found to be superior to both norethisterone and conventional OCPs.

scholarly journals Dysfunctional uterine bleeding: ormeloxifene versus combined oral contraceptive pills

2018 ◽  
Vol 7 (9) ◽  
pp. 3610
Author(s):  
Sonia Luthra ◽  
A. D. Dwivedi
Keyword(s):  
Oral Contraceptive ◽  
Blood Loss ◽  
Endometrial Thickness ◽  
Uterine Bleeding ◽  
Dysfunctional Uterine Bleeding ◽  
Oral Contraceptive Pills ◽  
Combined Oral Contraceptive ◽  
Contraceptive Pills ◽  
Group A ◽  
Group B

Background: Dysfunctional uterine bleeding is abnormal bleeding that occurs in the absence of recognizable pelvic pathology, general medical disease, or pregnancy.  Globally, health care systems are focusing on low morbidity and low cost therapeutic interventions. Hence, medical treatment for DUB is high on the priority list. This comparative study was conducted to analyse the efficacy of ormeloxifene and combined oral contraceptive pills in reducing the blood loss and endometrial thickness in cases of DUB.Methods: This prospective study was conducted on women with dysfunctional uterine bleeding, who attended Gynaecology OPD at Hind Institute of Medical Sciences, between August 2015 and April 2016. After applying inclusion and exclusion criteria, 72 women diagnosed with DUB were enrolled randomly in two groups A and B. Group A was treated by Ormeloxifene and Group B patients were treated with combined oral contraceptive pills for three consecutive cycles. The efficacies of the studied drugs were compared by analyzing the mean change in the pre and post treatment PBAC score, haemoglobin level and endometrial thickness using unpaired t-test.Results: Ormeloxifene was found to be significantly more effective (p <0.0001) than OCPs in controlling the menstrual blood loss (79% reduction in group A Vs 55.5% reduction in group B). Reduction in endometrial thickness was also more in the group receiving Ormrloxifene, however this was statistically not significant (p = 0.19). No major side effect observed with the use of Ormeloxifene.Conclusions: Ormeloxifene can be an effective and safe therapy in the treatment of Dysfunctional uterine bleeding.

Clinical Evaluation of Puberty Menorrhagia -A Study of Fifty Cases

2014 ◽  
Vol 23 (Number 2) ◽  
pp. 27-34
Author(s):  
K S Begum ◽  
H Begum ◽  
K Sultana ◽  
F A Begum ◽  
D Barua
Keyword(s):  
Oral Contraceptive ◽  
Private Practice ◽  
Uterine Bleeding ◽  
Dysfunctional Uterine Bleeding ◽  
College Hospital ◽  
Excessive Bleeding ◽  
Cross Sectional ◽  
Oral Contraceptive Pills ◽  
Combined Oral Contraceptive ◽  
Contraceptive Pills

This study was done to find out the causes of puberty menorrhagia and to evaluate the efficacy of various treatment applied in this disorder. This Descriptive cross sectional study was conducted in the Obstetrics and Gynaecology department of MARKS Medical College Hospital and in my private practice settingfrom August 2012 to February 2014. Fifty unmarried girls from age of menarche to 19 years with history of excessive bleeding per vagina attending in my private practice and out patient department or admitted to this Hospital, were included in the study. They were prospectively analysed to assess the aetiological factors and the outcome of treatment required to manage these cases. The most common cause of menorrhagia was Dysfunctional Uterine Bleeding (DUB) (82%), followed by Polycystic Ovarian Syndrome(10%) and Hypothyroidism(6%). Thirty (60%) patients had menorrhagia of > 1 years duration and majority of them 48 patients (96%) were labeled anaemic at the time of presentation. All patients responded well to medical management. Non-steroidal anti-inflammatory drugs and anti fibrinolytic agents produced 75% subjective improvements in complaints. However, the Hormonal treatment (Pogesterone and combined oral contraceptive pills) produced 72% improvement. Regarding the treatment outcome, the NSAIDS and anti fibrinolytic drugs were found to be most effective, in reducing the complaints of menstrual blood loses etc. so these should be used as first line of treatment in this disorder. Pogesterone and combined oral contraceptive pills should be used as 2nd line of treatment. Puberty menorrhagia is a distressing condition both for the patient as well as her parents. Most of the cases are due to anovulatory dysfunctional uterine bleeding (DUB) which is a self limiting condition. Counselling of the patients is an important part of management. Long term medical treatment is successful in the majority of cases.

scholarly journals Efficacy of ormeloxifene in comparison to oral contraceptive pills in medical management of dysfunctional uterine bleeding

2016 ◽  
Vol 3 (4) ◽  
pp. 244
Author(s):  
Nirmala Jaget Lakkawar ◽  
Padma Alaganandam ◽  
S. Yasodha
Keyword(s):  
Oral Contraceptive ◽  
Side Effects ◽  
Blood Loss ◽  
Endometrial Thickness ◽  
Uterine Bleeding ◽  
Dysfunctional Uterine Bleeding ◽  
Oral Contraceptive Pills ◽  
Combined Oral Contraceptive ◽  
Contraceptive Pills

<p class="abstract"><strong>Background:</strong> <span lang="EN-IN">Menstrual disorders are the most common gynecological condition resulting in hospital referrals.   Dysfunctional Uterine Bleeding is an abnormal uterine bleeding, in the absence of any organic, systemic or iatrogenic cause. Among women in reproductive age, one in 20 consults her general practitioner each year with menorrhagia. This condition can be managed both medically and surgically. Pharmacological treatment options available for DUB are combined oral contraceptive pills, progestogens, danazol, gonadotrophin releasing hormone (GnRH) agonists, prostaglandin synthetase inhibitor, anti-fibrinolytics and ethamsylate.  Role of ormeloxifene in dysfunctional uterine bleeding (DUB) is still in an exploring level.</span>The purpose of the study was <span lang="EN-IN">to evaluate the efficacy of ormeloxifene in the treatment of DUB and compare the effects of ormeloxifene with combined oral contraceptive pills for the control of DUB. </span></p><p class="abstract"><strong>Methods:</strong> <span lang="EN-IN">Sixty women presenting with DUB were randomly allocated to 2 equal groups, Group A were given ormeloxifene tablet @ 60 mg twice a week for 12 weeks, followed by 60 mg once a week for 12 weeks. Group B were given low dose combined oral contraceptive pills (OCP) containing 30 microgram ethinyloestradiol and 150 microgram levonorgestrel from day 1 to day 21st of the menstrual cycle for 6 cycles. The various parameters studied were reduction in menstrual blood loss which was measured by fall in pictorial blood loss assessment chart (PBAC) score, rise in haemoglobin (Hb) level and reduction in endometrial thickness, any drug side effects, compliance with the drug, dosage schedule and effect on quality of life after each month and at the end of trial period of 6 months. Patient’s level of satisfaction was assessed by improvement in Hb concentration, sense of wellbeing as well as overall general health, quality of life, sexual life and comfort with the continuation of the same drug.</span></p><p class="abstract"><strong>Results:</strong> <span lang="EN-IN">Mean blood loss (PBAC score) following treatment showed significant reduction in both the groups, however this reduction was comparatively high in ormeloxifene treated group. The various parameters to assess the subjective and clinical improvement at the end 3 and 6 months post treatment showed significant improvement in both the treatment groups; however ormeloxifene group showed significantly better improvement in comparison to OCP group. Mean endometrial thickness also showed reduction in both the groups but more significant reduction was observed in ormeloxifene group as compared to OCP group following 6 months of treatment. Symptomatic relief and subjective feelings in relation to improvement of menstrual abnormalities, any undesirable side effects, about dosage compliance and any thought of discontinuing the drug by the patients indicated excellent control of menorrhagia in both the study group, which accounted for 86.66% in ormeloxifene group and 80% of individuals in OCP group.  </span></p><p class="abstract"><strong>Conclusions:</strong> ORM is effective in control of DUB and can be used as an alternative to OCP for treatment of DUB with possibly minimal side effects and better dosage compliance.</p>

Sign in / Sign up

Export Citation Format

Share Document